Golden has been acquired by ComplyAdvantage.Read about it here ⟶

Precirix NV

Precirix is a private, clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing novel radiopharmaceuticals, using camelid-derived single-domain antibodies (sdAb) labeled with radioisotopes.

Overview Structured Data Issues Contributors Activity

Is a

Company attributes

Industry

Biomedical engineering

Pharmaceutical industry

...

Location

0

B2X

CEO

0

Pitchbook URL

pitchbook.com/profiles...170966-08

Number of Employees (Ranges)

11 – 50

Email Address

info@precirix.com0

Phone Number

+32247993600

Full Address

Burgemeester Etienne Demunterlaan 1 B-1090 Brussels, Belgium0

Investors

Pontifax Venture Capital

0

Forbion Capital Partners

...

Founded Date

January 1, 2014

Total Funding Amount (USD)

130,870,000

Latest Funding Round Date

March 17, 2022

Also Known As

Precirix

Latest Funding Type

Country

Headquarters

Funding Round attributes

Funding Type

Funding Round Amount (USD)

88,000,000

Funding Round Date

March 1, 2022

Other attributes

Company Operating Status

Active

Latest Funding Round Amount (USD)

88,570,000

No article content yet.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more companies like Precirix NV

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.

Open Query Tool

Golden Query Tool